Test drug that helps map colon and rectal cancer during surgery
Part of Cancer, Digestive system clinical trials.
This Phase 3 study tests SGM-101, a drug used during surgery to help doctors better outline primary, recurrent, and spread (metastatic) colorectal cancer. It may improve how completely tumors are identified and removed during an operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for curative surgery for colorectal cancer (colon T3/T4 or rectal T3/T4), or for recurrent colorectal cancer, or for peritoneal spread of colorectal cancer
- If you are female who could become pregnant, you must have a negative urine pregnancy test and use reliable birth control starting 30 days before the injection and for 30 days after
- You have not had another active cancer recently (except certain skin cancers or an early cervix cancer that has been fully treated)
- You do not have appendiceal cancer (cancer of the appendix)
- Your blood and organ test results must be within allowed ranges (liver, kidney, blood counts, and blood bilirubin)
- You should not have HIV, hepatitis B, or hepatitis C that is positive, and you should not have a serious untreated infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a special fluorescent dye during laparoscopic surgery helps surgeons better see and remove rectal or sigmoid colon cancer. The goal is to see if this technique makes the surgery more precise and possibly improves outcomes.
This trial studies a device (CG-100) placed inside the bowel to see if it can improve safety and outcomes during surgery for colorectal cancer. You would be asked to follow extra study check-ins after your operation, and the team would monitor whether the device works as intended.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This trial tests a new drug called SOT109 for people with advanced colorectal cancer that can't be removed by surgery or has spread. The goal is to see if it is safe, how well it works, and how the body handles it.
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.